Femasys (FEMY) announced that it received the Medicines and Healthcare products Regulatory Agency, MHRA, approval for its FemBloc Permanent Birth Control, which signifies the product has met the required standards for safety, quality, and effectiveness in the United Kingdom, UK. This marks an important milestone in the Company’s efforts to expand the availability of this non-surgical permanent birth control option to women in Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY: